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Abstract: Paracrine interactions between malignant estrogen receptor positive (ER+) breast cancer
cells and breast adipose fibroblasts (BAFs) stimulate estrogen biosynthesis by aromatase in BAFs.
In breast cancer, mainly the cAMP-responsive promoter I.3/II-region mediates excessive aromatase
expression. A rare single nucleotide variant (SNV) in this promoter region, which caused 70%
reduction in promoter activity, was utilized for the identification of novel regulators of aromatase
expression. To this end, normal and mutant promoter activities were measured in luciferase
reporter gene assays. DNA-binding proteins were captured by DNA-affinity and identified by
mass spectrometry. The DNA binding of proteins was analyzed using electrophoretic mobility shift
assays, immunoprecipitation-based in vitro binding assays and by chromatin immunoprecipitation
in BAFs in vivo. Protein expression and parylation were analyzed by western blotting. Aromatase
activities and RNA-expression were measured in BAFs. Functional consequences of poly (ADP-ribose)
polymerase-1 (PARP-1) knock-out, rescue or overexpression, respectively, were analyzed in murine
embryonic fibroblasts (MEFs) and the 3T3-L1 cell model. In summary, PARP-1 and histone H1 (H1)
were identified as critical regulators of aromatase expression. PARP-1-binding to the SNV-region
was crucial for aromatase promoter activation. PARP-1 parylated H1 and competed with H1
for DNA-binding, thereby inhibiting its gene silencing action. In MEFs (PARP-1 knock-out and
wild-type) and BAFs, PARP-1-mediated induction of the aromatase promoter showed bi-phasic
dose responses in overexpression and inhibitor experiments, respectively. The HDAC-inhibitors
butyrate, panobinostat and selisistat enhanced promoter I.3/II-mediated gene expression dependent
on PARP-1-activity. Forskolin stimulation of BAFs increased promoter I.3/II-occupancy by PARP-1,
whereas SIRT-1 competed with PARP-1 for DNA binding but independently activated the promoter
I.3/II. Consistently, the inhibition of both PARP-1 and SIRT-1 increased the NAD+/NADH-ratio in
BAFs. This suggests that cellular NAD+/NADH ratios control the complex interactions of PARP-1, H1
and SIRT-1 and regulate the interplay of parylation and acetylation/de-acetylation events with low
NAD+/NADH ratios (reverse Warburg effect), promoting PARP-1 activation and estrogen synthesis
in BAFs. Therefore, PARP-1 inhibitors could be useful in the treatment of estrogen-dependent
breast cancers.
Keywords: breast cancer; estrogen synthesis; breast adipose fibroblasts; adipose stromal cells;
epigenetics; SIRT-1; PARP-1
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1. Introduction
Breast cancers are the cancers with the highest incidence in the female population in both the
United States and Germany [1,2]. Up to 50–80% of all breast cancers are estrogen receptor-positive
(ER+) [3]. Excessive amounts of adipose tissue are associated with a higher risk of breast cancer and
cells from adipose tissue release various factors supporting tumor growth [4]. A direct link exists
between malignant cells in ER+ breast cancers and breast adipose fibroblasts (BAFs) representing
cancer-associated fibroblasts (CAFs) derived from preadipocytes: namely, that paracrine interactions of
tumor cells and BAFs are essential for estrogen biosynthesis by the enzyme cytochrome P-450 aromatase
(gene CYP19A1, chromosome 15q21.2) in BAFs [5,6]. The expression of the aromatase gene is controlled
by a tissue-dependent promoter system. In cancer-associated BAFs, promoter usage is altered, with
promoters I.3 and II, normally not used in BAFs, driving increased transcription [7]. These promoters
are activated by tumor-derived factors, including prostaglandin E2 (PGE2), via cAMP-dependent
and cAMP-independent signaling mechanisms [8,9]. Thus, tumor-induced aromatase expression and
estrogen biosynthesis in BAFs promote ER+ tumor growth. When ER+ tumors become resistant to
endocrine therapies, a declined long-term outcome has been observed [10]. Therefore, despite there
being a large body of knowledge about the regulation of aromatase in relation to breast cancer, there
is still a need for new targetable mechanisms involved in the regulation of estrogen synthesis and
action [11].
The enzyme poly (ADP-ribose) polymerase 1 (PARP-1, gene PARP1) catalyzes the
poly-ADP-ribosylation (parylation) of target proteins through a NAD+-dependent mechanism. It
recognizes various substrate proteins via different binding motives [12] and is involved in cellular
processes related to DNA methylation, the regulation of splicing, chromatin modulation, DNA repair
and transcriptional co-regulation such as histone modifications. Furthermore, the histone deacetylase
(HDAC) sirtuin 1 (SIRT-1, gene SIRT1) and PARP-1 are partial antagonists in several functional contexts
due to their competition for NAD+, e.g., in response to DNA damage [13]. Presently, PARP-1 inhibition
is mainly utilized in the treatment of triple-negative breast cancers (TNBCs) [14], but not in the
treatment of ER+ breast cancers.
A potential relevance of PARP-1 inhibition in ER+ breast cancers might emerge from our functional
analyses of a new single nucleotide variant (SNV) within the aromatase promoter I.3/II-region
(SNV(T-241C); NC_000015.10:n.51243270T>C; GRCh38.p13 human genome reference). This SNV leads
to a 70% decrease in aromatase promoter I.3/II-mediated transcription. DNA-affinity purification and
mass spectrometry identified PARP-1 and histone H1 (genes HIST1H1A-E) as alternating binders of
this SNV region. A dose-dependent effect of PARP-1 as an enhancer of aromatase transcription was
established utilizing PARP-1-knockout MEFs and PARP-1 overexpression. Furthermore, a functional
interaction of PARP-1 and SIRT-1 was demonstrated through specific inhibitors and chromatin
immunoprecipitation (ChIP) in human BAFs. Thus, PARP-1 may be a potential new target in
estrogen-dependent breast tumors.
2. Materials and Methods
All chemicals used were of analytical or cell culture grade. All oligonucleotides were from
Metabion (Steinkirchen, Germany).
2.1. Cells and Cell Culture
3T3-L1 cells were obtained from ATCC (Manassas, VA, USA). The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Sigma, Taufkirchen, Germany) containing 10% (v/v) fetal bovine
serum (FBS) (PAN-Biotech, Aidenbach, Germany) and 40 µg/mL gentamicin. PARP-1 knock-out and
wild-type (wt) murine embryonic fibroblasts (MEFs) were kindly provided by Z. Wang [15]. The cells
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were cultured in DMEM containing 10% (v/v) FBS, 40 µg/mL gentamicin, 1 mM sodium pyruvate,
2 mM l-glutamine and 25 mM HEPES. Cell lines were obtained from the original sources (ATCC,
producer) and therefore were not reauthenticated. They were used for ten passages. Each stock was
tested negative for mycoplasma. Human BAFs were isolated from adipose tissue of healthy patients
undergoing cosmetic breast surgery. Patients gave informed written consent according to a protocol
approved by the ethics committee of the Jena University Hospital (Ref.-Nr. 4285-12/14). BAFs were
isolated and cultured in medium 199 containing 10% (v/v) FBS, and 40 µg/mL gentamicin, as described
previously [16]. Confluent primary human BAFs, resembling almost exclusively preadipocytes, were
subcultured only once. All cultured cells were maintained at 37 ◦C in a humidified atmosphere with
5% CO2 and 95% air content, except for T3-L1-preadipocytes, which were grown in 7.5% CO2 and
92.5% air.
All cell stimulations or inhibitions were performed for 24 h in a serum-free medium as described
previously [16]. Aromatase promoter I.3 and II was pharmacologically activated by 10 µM forskolin
(Cayman Chemicals, Ann Arbor, MI, USA) [6]. Furthermore, the cells were treated with PARP-1
inhibitor PJ34 (Selleck Chemicals S7300, Houston, TX, USA), HDAC class I/IIa inhibitor n-butyrate
(Sigma B5887, Taufkirchen, Germany), HDAC class I/II/IV inhibitor Panobinostat (LBH589, Selleck
Chemicals S1030) and SIRT-1 inhibitor selisistat (EX527, Selleck Chemicals S1541). Where appropriate,
DMSO and ethanol solvent controls were carried out in parallel.
2.2. Aromatase Activity Testing
The in vivo evaluation of aromatase function in BAFs was performed by the tritium water
release assay in 24-well plates as described previously [16,17]. All conditions were tested in triplicate
per experiment.
2.3. NAD+/NADH Quantification
NAD+/NADH in BAFs was quantified using the colorimetric EZScreenTM NAD+/NADH Assay
Kit (BioVision; Milpitas, CA, USA) according to manufacturer’s protocol. The NAD+ and NADH
extraction protocol was adapted from a published method [18].
2.4. Preparation of Soluble Nuclear Extracts
Preparation of soluble nuclear extracts was based on a method published by Wilde et al. [19].
The protein concentration was quantified by the Bradford method [20].
2.5. Isolation and Identification of Putative DNA-Binding Proteins
Putative aromatase promoter I.3/II-region binding proteins in soluble nuclear extracts from
3T3-L1 cells were purified using biotinylated oligonucleotides bound to M-280 streptavidin magnetic
dynabeads® (Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s protocol. Magnetic
beads (48 µL) in wash buffer I (2 M NaCl, 1 mM EDTA, 10 mM Tris/HCl, pH 7.5) were incubated
with 1200 pmol 5′-biotinylated normal sequence oligonucleotide (Appendix A, Table A1) for 20 min
under rotation. After 3 washing steps in wash buffer I, oligonucleotide-coupled beads were mixed
with 1800 µg soluble nuclear extract proteins (720 µL), 192 µL 10-fold binding buffer (1 M NaCl, 1 mM
EDTA, 0.5 M Tris/HCl, pH 7.5), 940.8 µL water and 19.2 µL poly-dI/dC (10 µg/µL), and incubated for
30 min under rotation at room temperature. After 3 washing steps in two sample volumes each of
wash buffer II (10% (v/v) 10-fold binding buffer, 37.5% (v/v) nuclear extraction buffer (20 mM HEPES
pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF), 52.5% (v/v)
water), protein-binding magnetic beads were resuspended in 20 µL 1.5-fold Laemmli sample buffer
(93.75 mM Tris/HCl pH 6.8, 3% (w/v) SDS, 15% (v/v) glycerin, 0.015% (w/v) bromphenol blue) without
2-mercaptoethanol. Thereafter, 0.5 mg/mL dithiothreitol (incubation 3 min, 95 ◦C) and 2 mg/mL
iodoacetamide (incubation 30 min, 37 ◦C) were added.
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The captured proteins were separated on 8% SDS-polyacrylamide gels [21], which were stained
with Coomassie-blue [22] or ruthenium-red [23], respectively. Subsequent proteomic analysis
was basically performed as described by Baldin et al. [24]. Specific oligonucleotide-binding
proteins were excised and digested with trypsin, as described in Shevchenko et al. [25]. Extracted
peptides (acetonitril/0.1% (v/v) trifluoroacetic acid; 1:1) were analyzed by MALDI-TOF MS and
Nano-ESI-Quadrupol-TOF MS.
MALDI-TOF MS: Extracted peptides were mixed with a saturated α-cyano-4-hydroxycinnamic
acid solution (dissolved in acetonitril), allowed to dry on a stainless-steel anchor chip target and
subsequently analyzed by MALDI-TOF-TOF (ultrafleXtreme; Bruker Daltonics, Bremen, Germany).
Nano-ESI-Quadrupol-TOF MS: The chromatographic separation of extracted peptides was
performed on an Acclaim Pep MAP RSLC column in an Ultimate 3000 nano RSLC Systems (Thermo
Fisher Scientific, Dreieich, Germany) (eluent A: 0.1% (v/v) formic acid in water; eluent B: 0.1% (v/v)
formic acid in a 90% (v/v) acetonitril/10% (v/v) water mix); gradient: 0–4 min 4% (v/v) eluent B, 4–36 min
to 35% (v/v) eluent B, 36–40 min to 50% (v/v) eluent B, 40–41 min to 96% (v/v) eluent B, 41–45 min 96%
(v/v) eluent B, 45–60 min 4% (v/v) eluent B. MS was done in first-generation microTOF-Q MS (Bruker
Daltonics, Bremen, Germany). The MS peaks were identified by searching the NCBI-database using
the MASCOT interface (MASCOT 2.1.03, Matrix Science, London, UK) with the following parameters:
Cys as S-carbamidomethyl-derivative and Met in oxidized form (variable), one missed cleavage-site,
peptide mass tolerance of 300 ppm (MALDI-TOF MS) or 100 ppm (Nano-ESI-Quadrupol-TOF MS).
Hits were considered significant according to the MASCOT score (p = 0.05). The database research was
improved by iterative recalibration and application of the peak rejection algorithm filter of the Score
Booster tool implemented into the Proteinscape 3.0 database software (Protagen Dortmund, Germany).
2.6. Electrophoretic Mobility Shift Assays
For electrophoretic mobility shift assays (EMSA), 10 µg soluble nuclear extract protein per
condition was incubated in the presence of binding buffer (50 mM Tris/HCl pH 7.5, 0.1 M NaCl,
0.1 mM EDTA, 5 mM 2-mercaptoethanol) for 30 min at 37 ◦C with various double-stranded probes
(Appendix A, Table A1)—25 pmol of a Cy5-labeled normal sequence probe (either alone or in the
presence of a 20-fold molar excess of an unlabeled normal sequence probe (competitor)), or 25 pmol of
a Cy5-labeled SNV-containing probe or Cy5-labeled quadruple mutation probe (complete destruction
of putative binding-sites). For antibody competition, 2 µL of anti-PARP-1 antibodies (Appendix A,
Table A2) were incubated for 30 min before the addition of probes. Separations were carried out
on a 6% non-denaturing acrylamide gel at 4 ◦C (18 cm, 300 V, and 70 min; [26]). The wet gels were
directly scanned on a Fuji FLA-3000 imaging system and quantified using the AIDA Software (Raytest,
Straubenhardt, Germany).
2.7. Immunoprecipitation-Based DNA-Binding Assay
An immunoprecipitation-based DNA-binding assay protocol was developed for PARP-1 and
histone H1, respectively. Soluble nuclear extract proteins (50 µg) were pre-incubated with 2 µL
pre-cleared (in soluble nuclear extract buffer) Protein G-Sepharose 4 Fast Flow (GE Healthcare, Freiburg,
Germany) at 4 ◦C in a rotator to eliminate proteins binding non-specifically to protein G. After
centrifugation of the pre-incubated samples (20 s, 12,000× g, 4 ◦C), the supernatants were transferred
into new tubes and incubated with either 1 µL anti-histone H1 or 1 µL anti-PARP-1 antibodies
(Appendix A, Table A2) for 24 h at 4 ◦C under constant rotation. After the antibody incubation, 20 µL
pre-cleared Protein G-Sepharose 4 Fast Flow was added and incubated for 4 h at 4 ◦C under constant
rotation. For the final isolation of anti-histone H1 or anti-PARP-1 immunoprecipitates, respectively, the
samples were washed three times in a three-fold volume of DNA-binding buffer C (20 mM HEPES
pH 7.9, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) with centrifugation after each step (20 s,
12,000× g, 4 ◦C). The final immunoprecipitates were resuspended in 8 µL buffer C.
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The DNA-binding reaction was a modification of the sample preparation protocol for
electrophoretic mobility shift assays, as described by Taylor et al. [26]. Immunoprecipitates in buffer C
(8 µL) were mixed with 1.7 µL 10-fold binding buffer (500 mM Tris/HCl pH 7.5, 1 M NaCl, 1 mM EDTA,
50 mM β-mercaptoethanol) and were incubated with 50 pmol fluorescence-labeled oligonucleotides
with normal sequence (either alone or in the presence of a 26-fold molar excess of an unlabeled normal
sequence competitor) or sequence with SNV (Appendix A, Table A1). For normal binding reactions, the
premix was added to 2 µL Cy5-labeled double-stranded oligonucleotides (25 pmol/µL) in 5.3 µL water.
For binding reactions in the presence of a competitor, 8µL immunoprecipitate, 2µL fluorescence-labeled
double-stranded oligonucleotides and 5.3 µL unlabeled competitor double-stranded oligonucleotides
(250 pmol/µL; same sequences as fluorescence-labeled oligonucleotides) were mixed. After incubation
for 30 min with rotation at room temperature in the dark, the samples were washed three times in
a three-fold sample volume of wash buffer (50% buffer C, 10% 10-fold binding buffer, 40% water),
followed by a 20 s centrifugation at 12,000× g at room temperature. Finally, the oligonucleotide-bound
immunoprecipitates were resuspended in 17 µL wash buffer and transferred to a well of a 96-well plate
for fluorescence measurement (excitation 600 nm; emission 670 nm, cut off 630 nm). As a control, the
unspecific binding of fluorescent oligonucleotides to Protein G-Sepharose 4 Fast Flow beads treated as
described above in the absence of antibodies was analyzed, resulting in negligible fluorescence signals.
All conditions were tested in triplicate per experiment.
2.8. Western Blotting
Precipitated proteins were separated on 10% SDS-polyacrylamide gels [21]. Proteins were
transferred onto PVDF membranes using semi-dry blotting at 0.8 mA/cm2 for 40 min [27]. After
blocking in WP-T buffer (10 mM Tris/HCl pH 7.5, 100 mM NaCl, 0.1% (v/v) Tween 20) with 5% (w/v)
skimmed milk powder, the membrane was incubated overnight with the primary antibodies (1:1,000
each; Appendix A, Table A2). After washing in WP-T buffer and further blocking in WP-T buffer with
5% (w/v) milk powder, the appropriate HRP-conjugated secondary antibodies were added (1:5,000,
goat anti-mouse or goat anti-rabbit, Santa Cruz Biotechnology, Dallas, TX, USA). The proteins were
detected using enhanced chemiluminescence.
2.9. Transfection and Luciferase Reporter Gene Assays
Half-confluent 3T3-L1 preadipocytes or PARP-1 knock-out or wt MEFs in 24-well plates were
transfected using Roti-Fect Plus (Carl Roth, Karlsruhe, Germany) according to the manufacturer’s
instructions and stimulated 24 h later. To quantify promoter activities, pGL3-basic firefly luciferase
plasmid containing aromatase promoter I.3/II with either a normal or SNV sequence were used
(Appendix A, Table A3). For PARP-1 overexpression, pSG9M-PARP-1 plasmid was used [28].
Furthermore, we utilized pRL-SV40 plasmid-expressing Renilla luciferase for normalization. All
conditions were tested in triplicate per experiment. The luciferase activity measurement was described
by Hampf and Gossen [29].
2.10. Chromatin Immunoprecipitation (ChIP)
The chromatin immunoprecipitation protocol is a modified version of that published by Weiske
and Huber [30]. BAFs from four 10 cm dishes per condition were used per experiment. For each
Protein G-based immunoprecipitation, 1 µg anti-histone H1, anti-PARP-1 or anti-SIRT-1 antibody was
used per 5 µg of cross-linked DNA, respectively (Appendix A, Table A2). PCR was carried out using
Paq5000 DNA-polymerase (Agilent Technologies, Waldbronn, Germany) in a Veriti® 96-Well Thermal
Cycler (Applied Biosystems, Darmstadt, Germany). Two SNV region-spanning primer sets were used
(Supplementary Materials, Table S1). The products were analyzed on 12% polyacrylamide gels stained
with ethidium bromide, as described previously [19].
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2.11. Quantification of Aromatase mRNA-Expression in BAFs
The quantification of full-length aromatase mRNA-expression and utilization of promoters I.3
and II, respectively, was performed by quantitative real-time PCR (qRT-PCR), as described in detail
by Wilde et al. [19]. Primer sequences are given in the Supplementary Materials, Table S1. All
conditions were tested in triplicate per experiment. The evaluation of the PCR results was done by the
∆∆CT-method [31].
2.12. Quantification of Aromatase Promoter-Utilization in Transfected PARP-1 Wild-Type and
Knock-Out MEFs
Murine PARP-1 wild-type and knock-out MEFs were transfected using pGL3-PII-522 wt plasmid,
as described (Appendix A, Table A3). After 24 h of forskolin stimulation, DNA and mRNA were isolated
using the AllPrep DNA/RNA Mini Kit (Qiagen; Hilden, Germany) with on-column DNA-digestion
during the RNA-isolation. cDNA was synthesized as described [19]. The ABsolute SYBR Green Rox
Mix (Thermo Scientific; Schwerte, Germany) was used for qRT-PCR in a StepOnePlus™ real-time PCR
system (Applied Biosystems). The transfected aromatase promoter-dependent expression of luciferase
or the expected fusion sequences containing 5′-ends from aromatase exon I.3 (derived from the 5′-
or 3′-region of exon I.3, respectively) and a 3′-ends derived from luciferase were measured using the
primers described in the Supplementary Materials, Table S1, and cDNA as templates. Furthermore,
the amounts of firefly luciferase in relation to murine glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were measured using isolated DNA from the same cells as the templates, enabling a
correction for transfection efficiencies. All conditions were tested in triplicate per experiment. The
evaluation of the PCR results was performed by an accordingly modified ∆∆CT-method [31].
2.13. Statistical Analyses
Statistical analyses of all experiments and creation of diagrams were carried out using SigmaPlot
13 software (Systat Software GmbH, Erkrath, Germany). The data are presented as means ± sem or
using box plots, were appropriate. Initial normal distribution of values was tested by the method of
Shapiro-Wilk. Normally distributed values were compared to another group by Student´s t-test or
by one-way ANOVA for multiple comparisons. In the case of non-normally distributed values, two
groups were compared by the Mann–Whitney U-test. For all tests, the significance criterion p < 0.05
was used.
3. Results
3.1. SNV-Dependent Protein Complex Formation in the Aromatase Promoter I.3/II Region
We identified a new, extremely rare single nucleotide variant (SNV) in the aromatase promoter
I.3/II-region of a healthy DNA-donor (SNV(T-241C); NC_000015.10:n.51243270T>C; GRCh38.p7 human
genome reference; Supplementary Materials, Figure S1). This SNV decreased aromatase promoter I.3/II
activity in luciferase-reporter gene assays in 3T3-L1 cells by up to 70%, when the cells were stimulated
with the cAMP-elevating agonists di-butyryl-cAMP or forskolin (Figure 1A). This indicates a crucial
role for the base-pair at position −241 in relation to the transcriptional start site (TSS) of aromatase
promoter II. Two specific protein–oligonucleotide complexes could be identified in soluble nuclear
extracts from 3T3-L1 preadipocytes in EMSAs using normal and SNV-containing oligonucleotides,
respectively (Figure 1B). Complex formation was independent of forskolin, which induces an increase in
cAMP and thereby mimics cancer-related aromatase promoter I.3/II activation. Furthermore, complex
1 was only formed with wild-type oligonucleotide, but not on the SNV-containing oligonucleotide or
an extended quadruple mutation thereof. Complex 2 was not affected by the SNV. This indicates that
the formation of complex 1 might be necessary for the full induction of aromatase transcription.
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3.2. PARP-1 and Histone H1-Isoforms Bind to the SNV-Region
We subsequently identified the DNA-binding protein(s) of the SNV-dependent complex 1.
Firstly, DNA-bindi g proteins from nuclear ts of 3T3-L1 cells were purified with SNV
sequence-contai ing oligonucleotides coupl netic beads. After DS-PAGE, a 110 kDa
protein was detectable and ide tified by mass spectrometry as PARP-1 (Figure 2A and Supplementary
Materials, Table S2). The formation of complex 1 was blocked by anti-PARP-1 antibody in EMSA with
soluble nuclear extracts of 3T3-L1 cells, confirming PARP-1 as a component of complex 1 (Figure 2B).
Similar experiments were performed with nuclear extracts from PARP-1 wild-type and knock-out
MEFs to confirm this observation (Figure 2C,D). In PARP-1 wild-type MEFs, the formation of complex
1 on wild-type oligonucleotide was inhibited by anti-PARP-1 antibody or when a mutated probe was
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used, confirming the results from the 3T3-L1 cells described above. Furthermore, PARP-1-containing
complex 1 (but not complex 2) was massively reduced in PARP-1 knock-out MEFs.
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Figure 2. PARP-1 and H1 bind to the wild-type aromat se promote . / gion. (A) PARP- (110 kDa)
and histone H1 (32 kDa) were purified by DNA-affinity pull-down from soluble nuclear extract of 3T3-L1
cells using biotinylated wild-type oligonucleotide. Specifically binding (left) and non-specifically
binding (right) proteins were separated by SDS-PAGE and detected by Coomassie Blue staining.
Proteins identified by mass spectrometry are indicated by arrows (see also Supplementary Materials,
Figure S2). MW, molecular weight. (B) Complex 1 from soluble nuclear extracts from 3T3-L1 cells
was inhibited by competitor and anti-PARP-1 antibodies (ab) (n = 4; * p < 0.05). (C) Soluble nuclear
extracts from PARP-1 wild-type (+/+) MEFs or PARP-1 knock-out (−/−) MEFs were used for EMSAs.
Complexes 1 and 2 were inhibited by the competitor, but only complex 1 formation was suppressed
when using SNV (1m)- or quadruple mutation (4m)-containing probes. Furthermore, the formation of
complex 1 was inhibited by anti-PARP-1 antibodies and was strongly reduced in PARP-1 (−/−) MEFs
(n = 3; * p < 0.05 for (−/−) versus (+/+); # p < 0.05 for treatments compared with corresponding normal
sequence treatment). (D) Western blot detects no PARP-1 in PARP-1 knock-out MEFs.
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In addition to PARP-1, a second protein band of 32 kDa, specifically binding to the aromatase
promoter I.3/II-region, was detectable and identified by mass spectrometry as histone H1-isoforms
(Figure 2A and Supplementary Materials, Table S2).
3.3. PARP-1 and Histone H1 Compete for Binding to the Aromatase Promoter I.3/II-Region
In competition experiments using biotin-labeled oligonucleotides for pull-down of associated
proteins from 3T3-L1-cell nuclear extracts with magnetic beads, PARP-1 was detectable as the
dominant binding protein in ruthenium-stained gels and on western blots (Figure 3A). The addition
of a 10-fold molar excess of non-biotinylated competitor oligonucleotide displaced PARP-1 and
caused a prominent histone H1-binding. This asymmetrical competition suggests that PARP-1 is a
high-affinity/low-concentration binder of the aromatase promoter I.3/II-region, whereas histone H1
represents a low-affinity/high-concentration binder.
Immunoprecipitation-coupled DNA-binding assays using 3T3-L1 nuclear extracts accessorily
revealed the involvement of PARP-1 (Figure 3B). Immunoprecipitated PARP-1 revealed a similarly
weak binding to an SNV-containing probe (1m), as it did to a wild-type probe in the presence of
competitor oligonucleotides. In contrast, immunoprecipitated histone H1 revealed an even greater
binding to the SNV-containing probe (1m).
3.4. Histone H1 Is Parylated
The molecular weight of unmodified murine histone H1 is 21.79 kDa (uniProtKb database).
Nonetheless, histone H1 pulled-down with oligonucleotide-coupled magnetic beads from 3T3-L1
nuclear extracts revealed an apparent molecular mass of 32 kDa (Figure 3A). Western blot analysis of
immunoprecipitated histone H1 with a parylation-specific antibody detected a parylated 32 kDa-band
(Figure 3C). This observation suggests that PARP-1-catalyzed parylation caused the observed mass
shift of histone H1.
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Figure 3. PARP-1 and histone H1 are part of a regulatory system. (A) Putative binding proteins
in 200 µg soluble nuclear extract of 3T3-L1 cells were purified using magnetic dynabeads® M-280
streptavidin. The beads bound 133 pmol biotinylated oligonucleotides, either alone or in the presence
of a 10-fold molar excess of an unlabeled normal sequence oligonucleotide (competitor). After this,
SDS-PAGE-bound proteins were detected by ruthenium-staining and subsequent western blotting. The
addition of a competitor displaced PARP-1 and enabled histone H1 binding. (B) PARP-1 or histone
H1 isolated from soluble nuclear extracts of 3T3-L1 cells by immunoprecipitation bound to wild-type
sequence probe (n). Binding to the fluorescent probe was inhibited by the competitor (comp). The
SNV-containing fluorescent probe (1m) revealed reduced binding to PARP-1 but increased binding to
histone H1 (n = 3, * p < 0.05 for comp or 1m versus n). (C) Western blot using immunoprecipitated
histone H1 from 3T3-L1 cell soluble nuclear extract. Parylation was detected by parylation-specific
antibodies. In lane 1, anti-histone H1 ab indicates the loading of an excess of the pure antibody used
for immunoprecipitation. The asterisk marks the 32 kDa-band of parylated histone H1.
3.5. A Dual Role for PARP-1 on the Aromatase Promoter I.3/II
Having identified that PARP-1 preferentially binds to the wild-type sequence in the SNV-region, we
subsequently endeavored to elucidate the functional consequence of this interaction on the aromatase
promoter I.3/II activity. The overexpression of PARP-1 in 3T3-L1 cells res lted i increased firefly
luciferase activity, which was even more promine t after forskolin stimulation (Figure 4A). Similar
results were observed in PARP-1 knock-out MEFs, where PARP-1 overexpression led to biphasic
dose response (Figure 4B). The m xima of luciferase activities were measured when 150 ng PARP-1
expression plasmid per well was used for transfection and analysis was perform d with the reporter
gene plasmid containing the wild-type aromatase promoter I.3/II sequence and 75 ng/well using the
SNV-sequence. A further increase in PARP-1 xpressio plasmid resulted in significantly lower report r
gene activity.
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Figure 4. SNV-dependent aromatase expression depends on PARP-1 activity. (A) 3T3-L1 cells
were transfected with aromatase promoter I.3/II-containing pGL3-PII-522 wt firefly luciferase
reporter-plasmids and pRL-SV40. PARP-1 overexpression with 300 ng pSG9M-PARP-1 plasmid
increased luciferase activity (PARP-1; n = 8; * p < 0.05). (B) PARP-1 (−/−) MEFs were transfected
with pGL3-PII-522 wt or SNV-containing pGL3-PII-522(T-241C) plasmid. PARP-1 overexpression by
co-transfection with pSG9M-PARP-1 resulted in biphasic responses of luciferase activities (n = 8;
* p < 0.05; PARP-1 overexpression versus 0 ng; # p < 0.05 wt versus SNV-containing plasmid).
(C) PARP-1(−/−) and PARP-1(+/+) MEFs were transfected with pGL3-PII-522 wt plasmids. Aromatase
promoter usage on plasmids was measured by qRT-PCR (amplicons are indicated in the scheme; fluc,
firefly luciferase), which was normalized to plasmid-DNA, measured by qPCR. The expression of
luciferase including exon I.3 (5′- and 3′-regions, respectively) was similarly positively affected by
PARP-1 expression (n = 3; * p < 0.05 PARP-1(+/+) versus PARP-1(−/−) MEFs). Right panel depicts
expression ratios. (D) 3T3-L1 cells were transfected with the indicated plasmids and stimulated with
forskolin. PARP-1-inhibition by PJ34 increased luciferase activity only on the wild-type-promoter I.3/II
construct (n = 6; # p < 0.05 wt versus SNV-containing plasmid). (E–H) In forskolin-stimulated BAFs,
the expression of (E) total aromatase, (F) promoter I.3- or (G) promoter II-containing transcripts, and
(H) aromatase enzymatic activity were measured in the presence and absence of the PARP-1 inhibitor
PJ34. Similar biphasic dose-response curves were obtained for all parameters (n = 3; * p < 0.05 versus
controls without PJ34).
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Of note, however, is that in the dual-reporter gene assays, PARP-1 overexpression also massively
induced the Renilla luciferase vector (Appendix B, Figure A1A). Therefore, we validated and confirmed
the inducing effect of PARP-1 on the aromatase promoter region by another approach. PARP-1
knock-out or wild-type MEFs were transfected with the reporter plasmid containing the normal
aromatase promoter I.3/II sequence (pGL3-PII-522 wt) and analyzed by RT-qPCR for transcribed
mRNAs, which could be normalized exactly via qPCR for the transfected plasmid-DNA. Three
amplicons (firefly luciferase-specific, exon I.3-5′-region-specific and exon I.3-3′-region-specific) were
tested and revealed a massive 15–40-fold inducing effect of PARP-1 on promoter I.3/II-dependent
aromatase transcription (Figure 4C). Taken together, PARP-1 binding clearly affects the aromatase
promoter I.3/II-region.
Based on these observations, we hypothesized that the inhibition of PARP-1-activity should inhibit
aromatase promoter activity. Surprisingly, we observed that treatment with the PARP-1-inhibitor PJ34
resulted in a dose-dependent increase in reporter gene activities of the firefly luciferase promoter
I.3/II wild-type-construct (Figure 4D) and of the Renilla-vector (Appendix A, Figure A1B) in 3T3-L1
cells. This suggests that PARP-1 may also possess inhibitory potential. In contrast, total aromatase
expression regulated by promoters I.3 and II as well as aromatase enzyme activity were inhibited
by PJ34 in biphasic dose-responses in BAFs (Figure 4E–H). The strongest inhibition was observed
with 5–7 µM PJ34, whereas higher concentrations almost restored these values to those of untreated
cells. Taken together, these data suggested a dose- and cell type-dependent dual role of PARP-1 in the
regulation of aromatase promoter I.3/II activity. Moreover, both of the transcriptional start sites within
the promoter I.3/II-region are affected [7].
3.6. HDACs Modify Aromatase Promoter I.3/II Activity
Deacetylation is known to affect PARP-1 and histone H1 function [32,33]. Therefore, HDAC
inhibitors were screened in aromatase promoter I.3/II reporter gene assays in 3T3-L1 cells.
In forskolin-stimulated cells, the HDAC class I/IIa inhibitor N-butyrate increased luciferase activity,
which was significantly reduced by PJ34-mediated PARP-1 inhibition (Figure 5A), contrary to the effect
of PJ34-treatment in the absence of HDAC inhibitor (see Figure 4D), pointing to an interdependent
regulation. The class I/II/IV inhibitor panobinostat increased the aromatase promoter I.3/II driven
luciferase activity in both the wild-type and SNV-promoter genotypes (Figure 5B). The SIRT-1 (HDAC
class III) inhibitor selisistat, like n-butyrate, augmented luciferase activity, which was significantly
reduced by PARP-1 inhibition (Figure 5C). In contrast to panobinostat, the effect of selisistat could only
be observed with the normal sequence reporter, which is indicative of an antagonistic participation of
SIRT-1 in the control of the aromatase promoter I.3/II SNV-region by PARP-1.
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Figure 5. PARP-1 functionally interacts with histone deacetylases (HDACs). If not indicated otherwise,
cells were stimulated with forskolin. (A) pGL3-PII-522 wt-transfected 3T3-L1 cells were incubated
with n-butyrate, without or with PJ34 (n = 6; * p < 0.05 versus n-butyrate only; # p < 0.05 versus
controls). (B) 3T3-L1 cells transfected with pGL3-PII-522 wt or pGL3-PII-522(T-241C) were incubated
with panobinostat (n = 8; * p < 0.05 versus no panobinostat; # p < 0.05 wt versus T-241C), or (C) with
selisistat alone or in combination with PJ34 (n = 8; * p < 0.05 versus no PJ34; # p < 0.05 wt versus
T-241C). (D,E) Aromatase mRNA-expression or activity was measured in BAFs, which were treated
with selisistat without or with PARP-1 inhibitor PJ34. For better comparison, the data from BAFs
not treated with selisistat (control) were taken from Figure 4E–H (control). SIRT-1 inhibition alone
reduced aromatase expression and activity. (D) Control n = 3, selisistat n = 6; # p < 0.05 control versus
selisistat; (E) n = 3; * p < 0.05 versus no selisistat; # p < 0.05 control versus selisistat). (F) The increased
NAD+/NADH ratios were measured in forskolin-stimulated BAFs with the inhibition of PARP-1 (5 µM
PJ34) or/and SIRT-1 (200 nM selisistat) (n = 3; * p < 0.05 versus forskolin alone).
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Having identified selisistat/SIRT-1 as the most likely partner for PARP-1, we went back to
BAFs. Selisistat significantly inhibited total and promoter I.3/II-specific aromatase mRNA-expression
(Figure 5D) as well as aromatase activity in forskolin-treated BAFs (Figure 5E). Interestingly, we
observed a statistically not significant tendency for a biphasic dose response to PARP-1 inhibition in
the presence of selisistat in the RNA expression measurements, which was diametrically opposite
to the U-shaped PJ34 dose response of the controls. The large variances are due to widely differing
sensitivities of BAFs to selisistat. In the aromatase activity assays, these effects were not detectable,
probably due to interference with post-transcriptional effects of the inhibitors. In summary, SIRT-1 and
PARP-1 functionally interact in the control of aromatase expression.
Enzymatic activities of both PARP-1 and SIRT-1 depend on NAD+-consumption [13]. Despite the
presence of multiple other NAD+-metabolizing enzymes, the inhibition of PARP-1 or SIRT-1 or both
together resulted in increased NAD+/NADH ratios (Figure 5F), indicating that both enzymes consume
quite large amounts of, and compete at least locally for, NAD+.
3.7. Aromatase Expression Is Regulated by an Antagonizing System Including PARP-1, Histone H1
and SIRT-1
To conclusively verify the in vivo binding of PARP-1, histone H1 and SIRT-1 to the SNV-region in
the aromatase promoter I.3/II, we performed ChIP assays utilizing control and forskolin-stimulated
BAFs. Two overlapping primer sets covering the SNV-containing region of promoter I.3/II were used
(Figure 6A). In accordance with the results of the in vitro studies as described above, forskolin treatment
lead to a significantly increased PARP-1 binding, when analyzed with primer set 1 (Figure 6B,C).
The switch in promoter occupancy was even more obvious when ratios of PARP-1/SIRT-1 and of
PARP-1/histone H1 were analyzed (Figure 6D). Moreover, primer set 2 suggested that the partial
displacement of histone H1 and SIRT-1 by PARP-1 takes place in the immediate neighborhood of the
SNV-region (Figure 6E,F). Here too, the ratios of PARP-1/SIRT-1 and of PARP-1/histone H1 significantly
increased in forskolin-stimulated BAFs (Figure 6G), indicating the partial displacement of SIRT-1 and
histone H1 by PARP-1. Taken together, these results indicate that PARP-1, H1, and SIRT-1 directly
interact in an aromatase promoter I.3/II-region crucial for the induction in BAFs in the vicinity of breast
cancer cells in vivo.
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Figure 6. Dynamic interaction of PARP-1, SIRT-1 and histone H1 in the aromatase promoter I.3/II-region.
(A) PARP-1, histone H1 and SIRT-1 in vivo binding to the aromatase promoter I.3/II-region in +/−
forskolin-stimulated BAFs was analyzed by ChIP with two primer sets. The PCR products were
separated on 12% polyacrylamide gels and stained with ethidiumbromide. In, input (1:50 diluted
non-immunoprecipitated DNA); IP, immunoprecipitated samples; neg. control (protein G without
antibodies). ChIP primer sets 1 ((B–D), 266 bp amplicon) and 2 ((E–G), 87 bp amplicon) revealed similar
results (note that the forskolin-group image in E was cut and pasted to show the bands for PARP-1
and SIRT-1 in the general order of this figure; the original sample order is shown in Figure S2; the
smaller band is unspecific). Forskolin stimulation increased PARP-1 binding and increased ratios of
PARP-1/SIRT-1 and of PARP-1/histone H1 (n = 4; * p < 0.05 versus control).
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4. Discussion
Besides its role in DNA damage response and various other processes, the involvement of PARP-1
in transcriptional control has been established [34,35]. The identification of PARP-1 as a transcriptional
regulator of aromatase expression signifies the promoter I.3/II-region of aromatase as one of PARP-1´s
many targets [36]. More recently, PARP-1 received attention as a therapeutic target in TNBC and is
currently the subject of a series of clinical trials of specific inhibitors [14,37,38], based on its function
in DNA damage control. In addition, some authors have concluded that PARP-1 inhibition could be
useful in a broader range of breast cancers, including ER+ breast cancers (not necessarily mutated in
the BRCA DNA repair associated genes) [14,39].
Our study provides evidence that the inhibition of PARP-1 might be a pharmacological possibility
for treating ER+ breast cancers by targeting transcription. By happenstance, we have identified a new
rare SNV, located immediately downstream of the TATA-box of aromatase promoter I.3 (see Figure 7),
which strongly reduced reporter gene activity driven by the promoter I.3/II-region. Promoter I.3 is
intimately connected with promoter II, both functionally and by proximity (the transcriptional start-site
(TSS) of promoter II is only 226 bp downstream of the promoter I.3-TSS) [7,8]. PARP-1 preferentially
binds to the normal sequence of the SNV. The reduction in binding to the SNV variant in in vitro binding
assays was almost equal to a reduction in promotor activity in reporter gene assays, which strongly
suggests that PARP-1 is a critical component for the full induction of the breast cancer-associated
promoter I.3/II-region.
In principle, it seems counterintuitive that PARP-1 binding to a DNA site that at least overlaps with
the TATA-box core-promoter element should enhance transcription. However, several lines of evidence
clarify this supposed discrepancy. First, the binding location is typical for PARP-1, as Krishnakumar
et al. [36] identified the most probable PARP-1 accumulation to be about 250 bp upstream of TSSs in
their large-scale analysis of promoters, almost perfectly fitting the SNV-spacing of 241 bp upstream
of the promoter II TSS. Secondly, the overexpression of PARP-1 induces promoter I.3/II controlled
reporter gene activity in cell lines, whereas the inhibition of PARP-1 inhibits aromatase expression
and activity in BAFs. Thirdly, Wang et al. [40] found that the 5´-region of the non-coding exon I.3
inhibits the translation of the aromatase protein. The results of our qPCR-validation of the reporter
gene experiments in MEFs (see Figure 4C) reveal that the presence of PARP-1 leads to preferential
transcription of a 5´-truncated exon I.3, resulting in the omission of this inhibitory region. Taken
together, these findings indicate a central role of the SNV-region and PARP-1 for induction of aromatase.
We observed biphasic dose responses of the aromatase expression and enzyme activity of BAFs
treated with the PARP-1-inhibitor PJ34. This cannot be explained by a stand-alone action of PARP-1 at
the aromatase promoter. Furthermore, the overexpression of PARP-1 in PARP-1 knock-out MEFs also
resulted in a biphasic dose response, which might be caused by autoparylation at high concentrations
of PARP-1 and concomitant autoinhibition [41]. Taken together, all of the results suggest that PARP-1
must be part of a multifactorial system, in which interactions of different partners modulate the
aromatase promoter I.3/II activity (Figure 7).
One important interaction partner is histone H1 (H1), which co-purified with PARP-1 in our
assays. H1 even exhibited an increased binding to the mutant SNV sequence in line with the functional
association of H1 and PARP-1 reported in the literature [34]. Aubin et al. described euchromatin
formation by PARP-1-mediated H1 parylation and its displacement, resulting in gene activation [42].
PARP-1 inhibition reduced gene activity via H1-mediated heterochromatin formation. In this context,
such dynamic interactions of H1 and PARP-1 in large-scale analyses were reported by Krishnakumar
et al. [36]. Our competition experiments and ChIP analyses confirmed this dynamic regulation for the
aromatase promoter I.3/II-region as well. Interestingly, most of the H1 from 3T3-L1 cells was parylated.
In Western blots of immunoprecipitated H1, as well as in the DNA-coupled bead assays, we found a
size shift in H1 to 32 kDa, which is typical for parylation, as described by Huletsky et al. [43].
Cells 2020, 9, 427 17 of 23
Cells 2020, 9, x 17 of 23 
 
 
Figure 7. Model of PARP-1-dependent aromatase promoter I.3/II regulation. The aromatase promoter 
I.3/II-region is predominantly occupied by histone H1 and SIRT-1 (in concert with other HDACs) in 
un-stimulated BAFs. Signals activating promoter I.3/II trigger p300/CBP- or other histone 
acetyltransferase (HAT)-mediated acetylation of PARP-1 and H1. The resulting PARP-1 binding and 
activation boost displacement of H1 and SIRT-1 from the promoter by parylation. SIRT-1 activates 
promoter I.3/II by an unknown mechanism and, at high NAD+-concentrations, inhibits PARP-1 by 
deacetylation. Low NAD+-concentrations in tumor-associated BAFs favor PARP-1-activation and 
perpetuate H1- and SIRT-1-displacement. 
The involvement of H1 in aromatase promoter I.3/II regulation also indicates the involvement 
of HDACs. Besides the modulation of the nucleosome configuration by histone deacetylation, 
HDACs modify transcription factors [44]. HDAC class I/II/IV inhibition in 3T3-L1 cells increased the 
aromatase promoter I.3/II activity, while concurrent PARP-1-inhibition reduced its activity, 
indicating that acetylation events necessary for aromatase transcription need PARP-1 for a maximum 
effect. Contrarily, PARP-1 is activated through acetylation by p300/CBP, which can be reversed by 
class I HDACs [32]. 
TCTTATAATTTGGCAAGAAATTTGGCTTTC...NNNNNNN N...ATTATAAAA..TACAGCAC
promoter I.3
TATA-box
promoter II
TATA-box
promoter I.3
5´-TSS
promoter II
TSS
promoter I.3
3´-TSSSNV-position
TCTTATAATTTGGCAAGAAATTTGGCTTTC...NNNNNNN N...ATTATAAAA..TACAGCAC
promoter I.3
TATA-box
promoter II
TATA-box
promoter I.3
5´-TSS
promoter II
TSS
promoter I.3
3´-TSSSNV-position
PARP-1
PARP-1
histone
H1
histone
H1 SIRT-1
Unknowninteractionpartner(s)
HATs
class I/II/IV
HDACs
Ac
Ac
Ac
Ac
AcAc
Ac
Ac
Ac
Ac
p300/
CBP
SIRT-1
high[NAD ]+
[NAD ]+ low
+
+
(         )
(         )
Ac+
Ac+
? ? ?
Ac
Effect on promoter I.3/II 
- activation
- repression
Acetyl-group
Poly ADP-ribose
Promoter I.3/II
activating
signal
and/or decrease
of [NAD ]+
Figure 7. Model of PARP-1-dependent aromatase promoter I.3/II regulation. The aromatase promoter
I.3/II-region is predominantly occupied by histone H1 and SIRT-1 (in concert with other HDACs)
in un-stimulated BAFs. Signals activating promoter I.3/II trigger p300/CBP- or other histone
acetyltransferase (HAT)-mediated acetylation of PARP-1 and H1. The resulting PARP-1 binding
and activation boost displacement of H1 and SIRT-1 from the promoter by parylation. SIRT-1 activates
promoter I.3/II by an unknown mechanism and, at high NAD+-concentrations, inhibits PARP-1 by
deacetylation. Low NAD+-concentrations in tumor-associated BAFs favor PARP-1-activation and
perpetuate H1- and SIRT-1-displacement.
The involvement of H1 in aromatase promoter I.3/II regulation also indicates the involvement of
HDACs. Besides the modulation of the nucleosome configuration by histone deacetylation, HDACs
modify transcription factors [44]. HDAC class I/II/IV inhibition in 3T3-L1 cells increased the aromatase
promoter I.3/II activity, while concurrent PARP-1-inhibition reduced its activity, indicating that
acetylation events necessary for aromatase transcription need PARP-1 for a maximum effect. Contrarily,
PARP-1 is activated through acetylation by p300/CBP, which can be reversed by class I HDACs [32].
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Nonetheless, a special role in the functional relationship between HDACs and PARP-1 is assigned
to class III HDACs (sirtuins). Their deacetylase function involves a NAD+-dependent catalytic
mechanism [45] and, in particular, SIRT-1 mediates deacetylation of PARP-1 [46]. In our experiments,
SIRT-1 inhibition in 3T3-L1 cells resulted in similar effects as HDAC class I/II/IV inhibition. In contrast, in
BAFs SIRT-1 inhibition caused a reduction in aromatase expression and activity. This inhibition tended
to be alleviated in the presence of moderate concentrations of a PARP-1 inhibitor. In BAFs, SIRT-1 seems
to act as an aromatase promoter I.3/II activator. Taken together, experimental evidence suggests a strong
functional relationship between SIRT-1 and PARP-1, which may be modulated in a cell type-specific
manner. This functional link appears to be the NAD+-requirement of both enzymes [34,47,48].
Furthermore, SIRT-1 and PARP-1 have different kinetic features. The Michaelis constant (KM) of
PARP-1 is 20–60 µM NAD+ [49]. KM of SIRT-1 is 150–200 µM NAD+ [50]. Therefore, PARP-1 is more
active than SIRT-1 at low NAD+-levels, as can be observed, for example, in cardiomyocytes [51].
Conversely, high NAD+-levels favor increased SIRT-1 activation, leading to PARP-1 inhibition by
deacetylation (and inhibition of gene expression) [46]. In fact, in our ChIP experiments, a shift towards
stronger promoter I.3/II occupancy by PARP-1 upon forskolin stimulation could be observed.
Furthermore, with PARP-1 and SIRT-1 being involved in the regulation of aromatase expression,
the cellular context becomes important. BAFs in the neighborhood of tumor cells may exhibit a reverse
Warburg effect like CAFs [52]. This effect is well described for CAFs in breast cancers [53,54]. The
reverse Warburg effect is triggered by metabolites like lactate, released from tumor cells. In stromal
cells, their utilization can reduce the NAD+/NADH ratio [55]. The subsequently low NAD+-level
favors PARP-1-activity as compared to SIRT-1-activity.
The U-shaped dose responses to PARP-1 inhibition in BAFs result from an interaction with a partner,
which itself is functionally coupled to PARP-1 and stimulates aromatase expression independently.
Our observations using SIRT-1 inhibition in BAFs suggest that SIRT-1 is this partner. Active PARP-1
deprives SIRT-1 of NAD+, thus preventing its own inactivation by SIRT-1. Furthermore, PARP-1
supports euchromatin formation by H1-parylation (in addition to acetylation by acetyltransferases)
contributing to the activation of aromatase promoter I.3/II (Figure 7). Only under conditions of PARP-1
inhibition does the cellular NAD+-concentration increase to a sufficiently high level to allow SIRT-1 to
stimulate aromatase expression via, as of now, unidentified mechanisms.
5. Conclusions
In summary, PARP-1 is a key regulator of the aromatase promoter I.3/II activity, which can
be activated in BAFs by metabolic coupling to breast cancer cells. Lack of PARP-1 binding to the
promoter I.3/II region or PARP-1 inhibition, respectively, reduces aromatase expression as well as
estrogen synthesis in BAFs. Thus, low doses of PARP-1 inhibitors might be potentially useful for
estrogen-deprivation of ER+ breast cancers.
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Abbreviations
BAFs breast adipose fibroblasts
CAFs cancer-associated fibroblasts
ChIP chromatin immunoprecipitation
DMEM Dulbecco´s modified Eagle´s medium
EMSA electrophoretic mobility shift assay
ER+ estrogen receptor-positive
FBS fetal bovine serum
GAPDH glyceraldehyde 3-phosphate dehydrogenase
H1 histone H1
HDAC histone deacetylase
KM Michaelis constant
MALDI-TOF MS
matrix-assisted laser desorption/ionization–time-of-flight mass
spectrometry
MEF murine embryonic fibroblast
Nano-ESI-Quadrupol-TOF MS nano-electrospray ionization-quadrupol-time-of-flight mass spectrometry
PARP-1 poly (ADP-ribose) polymerase 1
p300/CBP p300/cAMP response element-binding protein acetylase
qRT-PCR quantitative real-time PCR
SIRT-1 NAD-dependent protein deacetylase sirtuin 1
SNV single nucleotide variant
TNBC triple-negative breast cancer
TSS transcriptional start-site
Wt wild-type
Appendix A
Table A1. Oligonucleotide sequences for protein identification, EMSA, DNA-affinity purification
and immunoprecipitation-based DNA-binding assay. Mutated positions/bases differing from the
GenBank-sequence are given in bold letters. Labels are at the 5′-ends.
Oligonucleotide/Label Forward Reverse
normal sequence
/label
5′-ctt ata att tgg caa gaa att-3′
Cy5
5′-att ttc ttg cca aat tat aag-3′
-
competitor with normal sequence 5′-ctt ata att tgg caa gaa att-3′ 5′-att ttc ttg cca aat tat aag-3′
sequence with SNV
/label
5′-ctt ata atc tgg caa gaa att-3′
Cy5
5′-aat ttc ttg cca gat tat aag-3′
-
sequence with quadruple
mutation
/label
5′-ctt ata atc cgg cgg gaa att-3′
Cy5
5′-aat ttc ccg ccg gat tat aag-3′
-
normal sequence
/label
5′-ctt ata att tgg caa gaa att-3′
biotin
5′-att ttc ttg cca aat tat aag-3′
-
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Table A2. Antibodies used in the experiments.
Target Protein Antibodies
histone H1 anti-histone H1 (AE-4): sc-8030, monoclonal mouse-antibodyIgG2a (Santa Cruz Biotechnology; Dallas, TX, USA)
PARP-1 mouse anti-PARP (C2-10): 556362, monoclonal mouse-antibodyIgG1 (BD PharmingenTM; Franklin Lakes, NJ, USA)
SIRT-1 anti-SIRT-1 (H-300): sc-15404, polyclonal rabbit-antibody (SantaCruz Biotechnology; Dallas, TX, USA)
parylated proteins anti-poly (ADP-ribose): 4335-MC-100, monoclonalmouse-antibody IgG3 (Trevigen; Gaithersburg, MD, USA)
Table A3. Plasmids for transfection and reporter gene assays.
Plasmid Name Function Amount Per Well
pGL3-basic empty vector of reporter gene plasmid with firefly luciferaseactivity 800 ng
pGL3-PII-522 wt wild-type-aromatase-promoter I.3/II-reporter gene plasmidwith firefly-luciferase-activity 800 ng
pGL3-PII-522 (T-241C) SNV containing aromatase-promoter I.3/II-reporter geneplasmid with firefly-luciferase-activity 800 ng
pRL-SV40 constitutively active Renilla-luciferase vector 50 ng
pSG9M empty vector 50 ng
pSG9M-PARP-1 constitutively active PARP-1 expression plasmid 50–600 ng
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Figure A1. PARP-1-dependent Renilla luciferase expression. (A) 3T3-L1 cells were transfected with 
aromatase promoter I.3/II-containing pGL3-PII-522 wt firefly luciferase reporter-plasmids and the 
Renilla luciferase pRL-SV40 reporter-plasmid. Cells were co-transfected with 300 ng pSG9M-PARP-1 
expression plasmid where indicated (PARP-1). PARP-1 overexpression increased Renilla luciferase 
activity (n = 8; * p < 0.05). (B) 3T3-L1 cells were transfected with pGL3-PII-522 wt (wild-type) or pGL3-
PII-522(T241C) together with pRL-SV40 plasmid expressing Renilla luciferase. In 10 µM forskolin-
stimulated cells PARP-1-inhibition by PJ34 tended to increase luciferase activity in combination with 
wild-type-promoter I.3/II (n = 6). 
References 
1. DeSantis, C.; Ma, J.; Bryan, L.; Jemal, A. Breast cancer statistics, 2013. CA Cancer J. Clin. 2014, 64, 52–62, 
doi:10.3322/caac.21203. 
2. Krebs in Deutschland 2007/2008. 8. Ausgabe. Robert Koch-Institut (Ed.) und die Gesellschaft der 
epidemiologischen Krebsregister in Deutschland e.V. (Ed). Berlin, 2012. Available online: 
http://dx.doi.org/10.25646/3161 (accessed on 12 September 2017). 
3. Huang, B.; Warner, M.; Gustafsson, J.A. Estrogen receptors in breast carcinogenesis and endocrine therapy. 
Mol. Cell Endocrinol. 2015, 418, 240–244, doi:10.1016/j.mce.2014.11.015. 
0
50
100
150
200
250
300
*
*
no
rm
ali
zed
 R
en
illa
luc
ife
ra
se 
ac
tiv
ity
 (R
LU
)
cont
rol
cont
rol +
 300 
ng P
ARP
-1 forsk
olin
forsk
olin 
+ 30
0 ng 
PAR
P-1
)
0 1 10
0
20
40
60
80
100
120
140
160
180
PJ34 (µM)
pGL3-PII-522(T-241C
pGL3-PII-522 wt
no
rm
ali
zed
 R
en
illa
luc
ife
ra
se 
ac
tiv
ity
 (R
LU
)
BA
Figure A1. PARP-1-dependent Renilla luciferase expression. (A) 3T3-L1 cells were transfected with
aromatase promoter I.3/II-containing pGL3-PII-522 wt firefly luciferase reporter-plasmids and the
Renilla luciferase pRL-SV40 reporter-plasmid. Cells were co-transfected with 300 ng pSG9M-PARP-1
expression plasmid where indicated (PARP-1). PARP-1 overexpression increased Renilla luciferase
activity (n = 8; * p < 0.05). (B) 3T3-L1 cells were transfected with pGL3-PII-522 wt (wild-type)
or pGL3-PII-522(T241C) together with pRL-SV40 plasmid expressing Renilla luciferase. In 10 µM
forskolin-stimulated cells PARP-1-inhibition by PJ34 tended to increase luciferase activity in combination
with wild-type-promoter I.3/II (n = 6).
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